Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force

Abstract

We recommend a framework for the BIA, provide guidance on the acquisition and use of data, and offer a common reporting format that will promote standardization and transparency. Adherence to these good research practice principles would not necessarily supersede jurisdiction-specific BIA guidelines but may support and enhance local recommendations or serve as a starting point for payers wishing to promulgate methodology guidelines.

Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis

“…33 Budget impact was calculated on a per-member-per-month basis for an approximate 2014 U.S. population of 320 million (U.S. Census Bureau, 2014). The calculation assumed that following implementation of blanket provider coverage, there would be an influx of about 30,000 transgender persons seeking transitional care in the first 5 years (i.e., 6000/year taken as the midpoint of 3000-9000 procedures per year according to Walsham).…”

Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa

“…For the purpose of cost-effectiveness analysis, we discounted both future costs and health benefits at a rate of 3% annually, also according to WHO guidelines [12]. Costs and health benefits remain undiscounted for the budget impact analysis [13]. We conducted both deterministic and probabilistic sensitivity analysis to evaluate the robustness of our findings in the face of parameter uncertainty.…”

“…To provide a fiscal planner with an estimate of the total cost of programme implementation, we calculated the undiscounted cost of different rabies control programmes over the same 10 year time horizon [13]. We incorporated the costs associated with both canine vaccination campaigns and PEP delivery; after PEP or death, there are no follow-up treatment costs associated with rabies.…”

Pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with HER2+ overexpression

“…Due to the long-term character of the evaluation (3 years), WHOrecommended discount rate of 3% should be applied according to the ISPOR guidelines for pharmacoeconomic forecasts [28,30].…”